The Claim
In adults with type 2 diabetes, once-weekly exenatide does not significantly reduce all-cause mortality or the composite outcome of death or heart failure hospitalization in those with preexisting heart failure (HR 1.05 and HR 1.07, respectively), whereas it is associated with a 21% reduction in mortality in those without heart failure, indicating that preexisting heart failure modifies the treatment effect of exenatide on cardiovascular outcomes.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
If you have type 2 diabetes and already have heart failure, the weekly diabetes shot exenatide might not help you live longer or keep you out of the hospital for heart problems. But if your heart is healthy, it could lower your risk of dying by 21%.
See the scientific wording
The cardiovascular benefits of once-weekly exenatide on all-cause death and the composite of death or heart failure hospitalization are attenuated in adults with type 2 diabetes who have preexisting heart failure, with no significant reduction in mortality (HR 1.05) or death/hospitalization (HR 1.07), in contrast to a 21% reduction in mortality in those without heart failure. This suggests that preexisting heart failure may modify the treatment effect of exenatide.
What the research says
1 studyThe study found that a diabetes drug called exenatide helped lower the risk of death in people without heart failure, but not in those who already had heart failure, which supports the claim.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.